FTI Consulting Named a Best Firm to Work For by Consulting Magazine for Third Consecutive Year

WASHINGTON, Nov. 18, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it has been named to Consulting magazine’s 2020 Best Firms to Work For list, the firm’s third consecutive year on the list.

The rankings are based on employee satisfaction surveys of more than 300 firms, focusing on the categories of culture, career development, client engagement, firm leadership, and compensation and benefits.

“This recognition captures the essence of what the firm stands for: helping our clients tackle their most pressing challenges and creating a platform for high-impact careers for great people,” said Steven H. Gunby, President and Chief Executive Officer of FTI Consulting.

Earning a top spot on Consulting’s Best Firms to Work For list follows other workplace honors for the firm this year. In April, FTI Consulting was named to Forbes magazine’s list of America’s Best Management Consulting Firms, recognized in 14 sectors and functional areas. Also in April, the firm’s Asset Lifecycle Management offering within its Construction Solutions practice was named a Vanguard Leader by ALM Intelligence, which evaluates firms on their ability to create impact according to input from clients and providers.

In July, the firm and its Compass Lexecon subsidiary were recognized as leading firms by Chambers Litigation Support 2020, a guide to top professional services providers in key markets worldwide, with 11 firmwide rankings and three individual rankings. Also in July, Global Arbitration Review (“GAR”) recognized FTI Consulting and Compass Lexecon as top expert witness firms in its annual GAR 100 Expert Witness Firms’ Power Index. Most recently, ALM Intelligence named FTI Consulting as a Pacesetter in financial crisis management.

About FTI Consulting

FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 6,200 employees located in 28 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $2.35 billion in revenues during fiscal year 2019. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn.

FTI Consulting, Inc.

555 12th Street NW
Washington, DC 20004
+1.202.312.9100

Investor
Contact
:

Mollie Hawkes
+1.617.747.1791
[email protected]

Media
Contact
:

Matthew Bashalany
+1.617.897.1545
[email protected]



REPEAT – Clean Power Capital Corp.’s Subsidiary, PowerTap Hydrogen Fueling, Announces That It Has Engaged NASA-Based Hydrogen Engineering Firm, Cryotek, as Its Engineering Design Partner to Commercialize Its Patented Hydrogen Filling Technology

VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6A)(OTC: MOTNF) (“Clean Poweror the “Company” or MOVE“). The Company’s 90 percent owned subsidiary PowerTap Hydrogen Fueling Corp. (“PowerTap”) is pleased to announce that it has partnered with Cryotek (cryotek.com) pursuant to an 8-month contract to provide engineering and design for the next generation PowerTap hydrogen filling stations, which is planned to be deployed across North America starting in 2021. The engineering design will include:

  • Next Generation PowerTap Onsite Steam Methane Reformer (“SMR”) solution capable of producing 1,000kg+ per day;
  • Gaseous and Liquid Hydrogen storage solutions capable of 1,000kg+ or more per day;
  • CO2 capture solutions;
  • Advanced hydrogen dispensing unit; and
  • Artist rendition of proposed final hydrogen filling station.

Cryotek is a hydrogen engineering firm led by CEO Cody Bateman. Mr. Bateman started this firm in 1989 as Advantex Research to focus on developing engineering solutions of complex problems associated with various industries including oil and gas, pharmaceuticals, airlines and energy. In 2018, the company was rebranded to Cryotek to focus on cryogenic solutions for NASA (USA National Aeronautics and Space Administration) and the USA Department of Energy. Since then, Cryotek has focused on the future of liquid hydrogen as the energy of the future and has become a leader in the field by developing smaller hydrogen steam methane reformation (SMR) units.

This is an excellent opportunity to work with PowerTap Hydrogen Fueling Corp. to combine our patented technologies, intellectual properties and trade secrets to deliver the next generation of the well-known PowerTap delivery system of hydrogen for the future. We have spent the last few months evaluating PowerTap’s intellectual property and design and we believe that by incorporating it with our proven technology that we will clearly have the most advanced, smallest footprint steam methane reformation hydrogen production solution and liquid storage for the trucking and automobile industry,” said Cody Bateman, CEO of Cryotek.

PowerTap is excited to work with Cryotek as our engineering and design partner to commercialize the next generation of PowerTap hydrogen filling stations. Cody Bateman and his world class engineering team are the ideal partner for PowerTap as we plan our aggressive roll out of hydrogen filling stations commencing in 2021,” said Raghu Kilambi, CEO of PowerTap Hydrogen Fueling Corp.

Hydrogen powered vehicles have major advantages over battery electric, gas, and diesel vehicles (driving range, quicker filling time and cost per mile). Billions of dollars’ worth of hydrogen long haul trucks and cars are expected on the market in next 2-4 years from incumbents and upstarts in the next 36 months. Hydrogen-powered vehicles generate electrical power in a fuel cell, emitting only water vapor and warm air.

The major advantage of this new technology over other hydrogen filling station systems is the small physical footprint for onsite hydrogen production and storage (700 Square Feet). These new modular stations are fabricated at a central manufacturing center and delivered to existing gas stations to augment their product offering. Each hydrogen station is then fully operational within two weeks from delivery. Most existing USA hydrogen filling stations must have their hydrogen delivered at a much higher costs than PowerTap’s on-site hydrogen production cost. PowerTap’s technology-based hydrogen filling stations are currently located in private enterprises and public stations in California, Texas, Massachusetts, and Maryland.

About
PowerTap

The Company acquired a 90 percent interest in PowerTap on October 27, 2020 (see the Company’s news release on October 28, 2020). PowerTap is leading the charge to build out cost-effective hydrogen fueling infrastructure through its environmentally friendly intellectual property, product design for the modularized and lowest tier production cost of hydrogen, and launch plan.   PowerTap technology-based hydrogen fueling stations are located in private enterprises and public stations (near LAX airport) in California, Texas, Massachusetts, and Maryland. Additional information about PowerTap may be found at its website at http://www.powertapfuels.com.

ABOUT
CLEAN POWER
CAPITAL CORP.

Clean Power is an investment company that specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in our investments. A copy of Clean Power’s amended and restated investment policy may be found under the Company’s profile at www.sedar.com.

ON BEHALF OF THE
CLEAN POWER
CAPITAL CORP.
BOARD OF DIRECTORS

“Joel Dumaresq”

Joel Dumaresq
CEO
+1 (604) 687-2038
[email protected]

Learn more about Clean Power by visiting our website at: https://cleanpower.capital/.

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Notice Regarding Forward Looking Information:

This press release contains “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Clean Power. Some assumptions include, without limitation, the development of hydrogen powered vehicles by vehicle makers, the adoption of hydrogen powered vehicles by the market, legislation and regulations favoring the use of hydrogen as an alternative energy source, the Company’s ability to build out its planned hydrogen fueling station network, and the Company’s ability to raise sufficient funds to fund its business plan. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur or be achieved. This press release contains forward-looking statements pertaining to, among other things, the timing and ability of the Company to complete any potential investments or acquisitions, if at all, and the timing thereof. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and, in some instances, to differ materially from those anticipated by the Company and described in the forward-looking information contained in this press release.

Although the Company believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.



What do the Pfizer Vaccine and BetterLife Pharma have in common?

New York City, Nov. 18, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotech company focused on development and commercialization of interferon (IFN) based therapeutics, recently provided a clinical and regulatory update for its AP-003 COVID-19 clinical trials using inhaled interferon alpha 2b.  While recent advancements in vaccines may seem to provide a glimmer of hope for bringing the pandemic to a close, it remains to be seen how safe and effective they will be, and for how long. The importance of life-saving COVID-19 therapeutics is as great ever, and the support for the Company’s use of interferon as a therapeutic for COVID-19 is compelling.

Recent research, summed up by an article from NBC which stated ‘’COVID-19 patients with life-threatening illness have antibodies that disable key immune system proteins called interferons’’, highlighted the latest findings on the importance of interferon and its role in fighting Covid-19  and other viral infections:

      ·Crucial Role of IFNs in Virus Infections

Type I IFNs are our natural first line of defence against ANY and ALL viruses. The human body has a non-specific surveillance system in all its cells, since any cell can be infected – that detects virus and immediately triggers a response in that cell.  This is true whether it is a respiratory virus targeting the airways and lungs (flu and coronaviruses), a virus that targets the liver (hepatitis B or C), the heart (Coxsackie virus), the gut (many enteric viruses), the brain (Zika), or whether the virus enters the skin through a mosquito bite (dengue, West Nile virus).

That immediate sensing of a virus leads immediately to the production of interferons – regardless of the virus. This is true for ALL viruses. 

This IFN response is highly important as some intelligent viruses have evolved to have specific genes that block this IFN response.  because viruses have co-evolved to very specifically have genes that will block this IFN response.   

According to Dr. Eleanor Fish, an expert on IFNs and member of the Scientific board for BetterLife, SARS-COV-2 (the virus responsible for COVID-19) has within its viral genome a number of such trigger genes that are turned on immediately after the virus infects cells in the hosts airways which in turn produces factors that block IFN production.

      ·Role of IFN (or lack thereof) in COVID-19

In the high profile publication referenced above, it was shown that not only does SARS CoV-2 blunt/diminish an IFN response, thereby disabling an effective immune response to this infection, but that those individuals who become infected that have low blood levels of IFN tend to experience a more severe illness.  Similarly, those individuals who have any mutations in genes associated with the IFN response also tend to have a more severe response to COVID-19.  Individuals who, for whatever reason, have antibodies to IFN, will also elicit a more severe COVID.  

 All this informs us of the importance of the IFN response in resolving COVID. 

      ·Pfizer Vaccine: an IFN Cell Modulator

The importance of IFN response has also been reflected in the development of the Pfizer vaccine.  The vaccine stimulates the production of IFN gamma in T Cells (responsible for fighting infections).  IFN gamma is Type II IFN.  Both Type I (the Company’s interferon alpha 2b) and type II interferons (are central to both combating virus infection and modulating the antiviral immune response.

      ·An inhalation form of IFN based product can play an important role in fighting MOST infections beyond COVID-19.
             
For every vaccine or drug that targets a specific aspect of a virus, viruses mutate and become drug resistant. Not so for IFNs: IFNs are produced by the immune system and are not virus-specific, thus there is no development of resistance to IFNs.

Notably, IFN targets many different stages of the virus life cycle – from blocking entry into cells, to preventing uncaring of enveloped viruses, to degrading the virus genome, to blocking the assembly of the virus particle and prevent virus form getting out of cells. When cells have a huge number of virus particles, IFN will kill the cell – and the virus. IFN will also recruit specific immune cells to a site of infection, and activate them to clear the infection. 

The Company has always maintained that the best approach to deal with virus infections are combination therapies, incorporating a cocktail of drugs that target different aspects of the virus.  

Dr. Ahmad Doroudian, CEO BetterLife , has mentioned in recent interviews that the best approach may well be combining IFN with remdesivir and/or the monoclonal antibodies being evaluated now.

Affordable treatments will always be important.  Remdesivir and monoclonal antibodies are very expensive and additionally are injected, not administered into the airways where the virus resides.

Dr. Doroudian  believes that that an inhaled IFN such as the Company’s AP-003 therapeutic that directly targets the airways and that is also affordable will have widespread utility for COVID-19 and any other respiratory infection that might appear in the future. 

While millions of people around the World may well have access to a vaccine eventually, there will be hundreds of thousands for whom the vaccine may well not work and will require effective treatment options.   AP-003 as both a treatment and preventative may well provide the solution for this unmet need, following conclusion of its imminent trials in Australia.

About BDA International, Inc.:

BDA International is an independent global firm offering a wide range of IR and PR related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including BETRF. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and BETRF may do so via the contact information at the bottom of this release.

Disclaimer

The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. BetterLife Pharma is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:
Dost Mushtaq                                                                      
BDA International    
www.bda-ir.com
[email protected]   



Atrium Expands Its Relationship With AWS to Boost Enterprise Analytics Capabilities

Atrium combines leading analytics technology platforms, AI expertise, and industry acumen to help AWS customers deliver business transformation

INDIANAPOLIS , Nov. 18, 2020 (GLOBE NEWSWIRE) — Atrium, a next-generation consulting company that leads enterprises through a business transformation with artificial intelligence (AI) and analytics, today announced it has expanded its relationship with Amazon Web Services (AWS) in order to further assist enterprises in leveraging their data through the power of AI. Atrium’s service offerings, powered by AWS, can help Atrium prospects and customers to further evolve their investments in business intelligence by improving access to AWS.

“When enterprise companies need innovation at scale, they turn to AWS. AWS has heavily invested in making cutting-edge AI and machine learning tooling, business intelligence services, and cloud infrastructure. With this relationship, we hope to more effectively bring these capabilities to our clients,” said Rick Arnett, Director of Enterprise Architecture at Atrium.

Leveraging this expanded relationship, Atrium will create unique service offerings focused on deploying predictive analytics and machine learning use cases with Amazon SageMaker and Amazon Redshift. Leveraging the power of AWS, Atrium can help companies with the evolution from operational reporting and analytics to predictive analytics in an environment of rapid migration to cloud-based analytics and AI. 

“AWS’s continued innovation as a cloud data platform is setting the standard for companies looking to dramatically accelerate their adoption of analytics and AI,” said Braden Larmon, VP of Alliances and Business Development at Atrium. “We look forward to working with AWS as we support our customers on their analytics journey and develop enterprise-wide use cases for AI.”

Atrium is currently developing playbooks to help the market frame the best approaches for merging the product roadmaps developed from Salesforce, Tableau, Snowflake, and other leading analytics providers. 

“We are very excited to be formalizing our relationship with AWS. In reality, most of us have been working with AWS for years, moving systems and applications from client data centers to the cloud,” said Lonnie Gray, Director of Enterprise Architecture at Atrium. “As an AWS Select Consulting Partner, we look forward to working with AWS and continuing to leverage services like Amazon SageMaker for our customers.” 

Atrium works with enterprise companies across diverse industries with a dedicated investment in supporting companies in financial services, life sciences, and higher education. For more information on Atrium and their relationship with AWS, visit atrium.ai/partners.

About Atrium:
Founded in 2018, Atrium is a next-generation consulting services company that helps organizations across diverse industries deliver on the promise of analytics and AI. As the market leader in intelligent solutions, we help organizations make smarter decisions and act on them. Learn more at atrium.ai.com.

Media Contact:

Jiordan Castle
[email protected]



Namaste Technologies Announces Proposed Transaction to Take Ownership of CannMart Labs to 100%

PR Newswire

~Namaste to acquire remaining 49% of CannMart Labs as it works through the final phase of its application for a processing licence from Health Canada~

TORONTO, Nov. 18, 2020 /PRNewswire/ – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF), a leading platform for cannabis products, accessories, and education, is pleased to announce it has entered into a share purchase agreement (the “Share Purchase Agreement“) to acquire the remaining 49% interest in CannMart Labs Inc. (“CannMart Labs“), an applicant for a processing licence under the Cannabis Act (Canada) for cannabis extraction activities.

Transaction Highlights:

  • Namaste to acquire remaining 49% of CannMart Labs to 100% ownership
  • CannMart Labs facility in Ontario is completed for BHO extraction using leading extraction technology, making it one of only a few facilities in Canada with such capabilities
  • Application in final phase for a processing licence from Health Canada
  • Set to produce in-house branded Cannabis 2.0 products for medical channel customers at CannMart.com and recreational customers across Canada through sister company CannMart Inc.’s network of provincial sales partners
  • Cannabis 2.0 products initially planned include shatter and live resin with capabilities to expand future distillate product offerings to vape cartridges, gel capsules, tinctures and edibles

In May 2018, Namaste acquired a 51% interest in CannMart Labs and agreed to finance the construction of its facility in Etobicoke, Ontario, a purpose-built oil extraction facility which incorporates a leading extraction technology facility designed to meet EU Good Manufacturing Practice (EU-GMP) certification requirements.

“Acquiring the remaining interest in CannMart Labs is another important milestone achieved in establishing Namaste as a leading company within the Canadian cannabis sector,” said Meni Morim, Chief Executive Officer of Namaste. “CannMart Labs is in the final stage of its application for an important processing licence from Health Canada. It has installed state-of-the-art extraction technology in its facility, which when granted a licence, will be able to produce an array of cannabis products including shatter and live resin, as well as future distillate products such as vape cartridges, gel capsules, tinctures and edibles.”

Mr Morim added: “This transaction is advantageous to Namaste shareholders as the Vendors will continue to provide management services and will receive earn-out payments in the form of Namaste common shares or cash only upon the successful achievement of certain revenue and gross profit targets and if the targets are met, the cash payment option allows Namaste to minimize dilution associated with the acquisition. We are working hard towards receiving our processing licence from Health Canada and look forward to producing in house branded Cannabis 2.0 products, for our medical channel customers at CannMart.com and recreational consumers across Canada through our network of provincial sales partners.”

Under the terms of the proposed transaction (the “Proposed Transaction“), Namaste will acquire the remaining 49% interest of CannMart Labs from MKD Holdings Inc. and JLLS Holdings Inc. (together, the “Vendors“) in exchange for a purchase price of $4,034,000 (the “Purchase Price“). A first tranche of the Purchase Price of $1,608,500 will be paid to the Vendors in common shares of Namaste issued at a deemed price equal to the seven day volume weighted average price of Namaste’s common shares on the TSX Venture Exchange (the “VWAP“) on the closing date of the Proposed Transaction. The remaining Purchase Price of $2,425,500 is payable to the Vendors in equal tranches over the next nine fiscal quarters beginning on the fiscal quarter ending February 28, 2021, at the VWAP on the date of issuance required within 5 days of the end of the applicable fiscal quarter.

The Vendors are also entitled to earn-out payments in the form of Namaste common shares, on a sliding scale, upon the achievement of pre-determined revenue targets (the “Earn-Out Payments“) which are also payable over the next nine fiscal quarters beginning on the fiscal quarter ended February 28, 2021. The maximum amount of each Earn-Out Payment payable to the Vendors in aggregate is capped at approximately $1.94M of Namaste common shares at the VWAP on the date of issuance required 15 days from publication of Namaste’s applicable quarterly financial statements. There is no minimum quarterly Earn-Out Payment.

Namaste has the option of paying any of the Purchase Price and any Earn-Out Payment (if any), in cash, subject to a five percent discount. Under the terms of the Share Purchase Agreement, the maximum number of common shares which may be issued to the Vendors is 64,466,942 (the “Maximum Share Number“) being 19.9% of Namaste’s currently outstanding common shares.  In the event Namaste wishes to issue common shares in excess of the Maximum Share Number in satisfaction of the Purchase Price or the Earn-Out Payments, Namaste would be required to seek further approvals from the TSX Venture Exchange.

MKD Holdings Inc., one of the Vendors, is controlled by a director and officer of CannMart Labs and the CannMart Labs’ shares held by this entity are beneficially owned by his wife. Accordingly, the Proposed Transaction is considered to be a Non-Arm’s Length Transaction under the policies of the TSX Venture Exchange.

Closing of the Proposed Transaction is subject to customary closing conditions, including final approval of the TSX Venture Exchange.

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a leading online platform for cannabis products, accessories, and responsible education. The Company’s ‘everything cannabis store’, CannMart.com, provides medical customers with a diverse selection of hand-picked products from a multitude of federally-licensed cultivators, all on one convenient site. The Company also distributes licensed and in-house branded cannabis and cannabis derived products to recreational consumers in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:
NamasteTechnologies.com
NamasteMD.com
Cannmart.com

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.

The forward-looking information contained herein, including, without limitation, statements related to completion of the Proposed Transaction, the issuance of a processing license by Health Canada to CannMart Labs, the production of cannabis products by CannMart Labs, the impact of the acquisition of CannMart Labs on the growth of the Company’s business and the benefits of the Proposed Transaction to Namaste shareholders, is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, the granting of a processing license to CannMart Labs, management’s perceptions of its ability to successfully produce cannabis products at the CannMart Labs’ facility, integrate CannMart Labs’ products into its business and Namaste’s standing in the online marketplace for cannabis products, Namaste’s beliefs regarding the quality of CannMart Labs’ management, the expected demand for Cannabis 2.0 products and the expected growth of that market, the Company’s ability to add to its product line, results of operations, operational matters, historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: regulatory risk, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/namaste-technologies-announces-proposed-transaction-to-take-ownership-of-cannmart-labs-to-100-301175862.html

SOURCE Namaste Technologies Inc.

Syneos Health Announces Senior Notes Offering

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced it commenced an offering of $500.0 million aggregate principal amount of senior notes (the “Notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Company’s subsidiaries.

Syneos Health intends to use the net proceeds of the offering for general corporate purposes, including the funding of acquisitions and the repayment of indebtedness.

The Company also announced that it intends to enter into an amendment to the credit agreement governing its existing senior secured credit facilities pursuant to which, among other things, the Company expects to extend the maturity date thereof to August 2024 (the “Amendment”). The closing of the offering is not conditioned upon the effectiveness of the Amendment.

The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States, only to non-U.S. investors pursuant to Regulation S. The Notes will not be and have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers of the Notes will be made only by means of a private offering memorandum.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: reliance on key personnel; principal investigators and patients; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; any inability to satisfy or any failure to waive the closing conditions related to our acquisition of SHCR Holdings Corporation (“Synteract”); any failure to realize the anticipated benefits of the acquisition of Synteract; risks related to the COVID-19 pandemic; the Company’s ability to adequately price its contracts and not overrun cost estimates; any adverse effects from the Company’s customer or therapeutic area concentration; the Company’s ability to maintain or generate new business awards; the Company’s ability to increase its market share, grow its business, and execute its growth strategies; the Company’s backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; fluctuations in the Company’s operating results and effective income tax rate; risks related to the Company’s information systems and cybersecurity; changes and costs of compliance with regulations related to data privacy; risks related to the United Kingdom’s withdrawal from the European Union; risks related to the Company’s transfer pricing policies; failure to perform services in accordance with contractual requirements, regulatory requirements and ethical considerations; risks relating to litigation and government investigations; risks associated with the Company’s early phase clinical facilities; insurance risk; risks of liability resulting from harm to patients; success of investments in the Company’s customers’ business or drugs; foreign currency exchange rate fluctuations; risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in our business; risks related to the Company’s income tax expense and tax reform; risks relating to the Company’s intellectual property; risks associated with the Company’s acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; potential violations of anti-corruption and anti-bribery laws; risks related to the Company’s dependence on third parties; downgrades of the Company’s credit ratings; competition in the biopharmaceutical services industry; changes in outsourcing trends; regulatory risks; trends in the Company’s customers’ businesses; the Company’s ability to keep pace with rapid technological change; risks related to the Company’s indebtedness; fluctuations in the Company’s financial results and stock price; and other risk factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other SEC filings, copies of which are available free of charge on the SEC website at www.sec.gov. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

About
Syneos
Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. 

Investor Relations Contact: Press/Media Contact:
   
Ronnie Speight Danielle DeForge
Senior Vice President, Investor Relations Executive Director, External Communications
Phone: +1 919 745 2745 Phone: +1 202 210 5992
Email: [email protected] Email: [email protected]



Simon Property Group Announces Commencement Of Offering Of Common Stock

PR Newswire

INDIANAPOLIS, Nov. 18, 2020 /PRNewswire/ — Simon Property Group, Inc. (NYSE: SPG) (“Simon” or the “Company”), a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, today announced that Simon has commenced an offering of 17,500,000 shares of common stock.  The Company expects to grant the underwriters an overallotment option to purchase up to 2,625,000 additional shares of common stock.

The Company intends to contribute the net proceeds from the offering to Simon Property Group, L.P. (the “Operating Partnership”), which intends to use such proceeds to fund the previously announced acquisition of an 80% interest in The Taubman Realty Group Limited Partnership (the “Taubman Acquisition”) in part and for other general business purposes, which may include, without limitation, repaying or repurchasing indebtedness, working capital and capital expenditures.

BofA Securities and Citigroup are serving as joint book-running managers of the offering. 

The offering is being conducted as a public offering under the Company’s effective shelf registration statement and a preliminary prospectus supplement and accompanying prospectus filed by the Company with the Securities and Exchange Commission (“SEC”).  Any offer of securities will be made by means of the prospectus supplement and accompanying prospectus.  The preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website at http://www.sec.gov.

When available, copies of the preliminary prospectus supplement and accompanying prospectus for the offering can be obtained by contacting: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: [email protected]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements
Certain statements made in this press release may be deemed “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in any forward–looking statements are based on reasonable assumptions, the Company can give no assurance that its expectations will be attained, and it is possible that the Company’s actual results may differ materially from those indicated by these forward–looking statements due to a variety of risks, uncertainties and other factors. Such factors include, but are not limited to: uncertainties regarding the impact of the COVID-19 pandemic and governmental restrictions intended to prevent its spread on our tenants’ businesses, financial condition, results of operations, cash flow and liquidity and our ability to access the capital markets, satisfy our debt service obligations and make distributions to our stockholders; the inability to collect rent due to the bankruptcy or insolvency of tenants or otherwise; changes in economic and market conditions that may adversely affect the general retail environment; the intensely competitive market environment in the retail industry; changes to applicable laws or regulations or the interpretation thereof; risks associated with the acquisition, development, redevelopment, expansion, leasing and management of properties; the inability to lease newly developed properties and renew leases and relet space at existing properties on favorable terms; the potential loss of anchor stores or major tenants; decreases in market rental rates; the impact of our substantial indebtedness on our future operations; any disruption in the financial markets that may adversely affect our ability to access capital for growth and satisfy our ongoing debt service requirements; any change in our credit rating; changes in market rates of interest and foreign exchange rates for foreign currencies; general risks related to real estate investments, including the illiquidity of real estate investments; security breaches that could compromise our information technology or infrastructure; risks relating to our joint venture properties; our continued ability to maintain our status as a REIT; changes in tax laws or regulations that result in adverse tax consequences; changes in the value of our investments in foreign entities; our ability to hedge interest rate and currency risk; changes in insurance costs; the availability of comprehensive insurance coverage; natural disasters; the potential for terrorist activities; environmental liabilities; the loss of key management personnel; the completion of the Taubman Acquisition and the use of proceeds from the offering; and the transition of LIBOR to an alternative reference rate. The Company discusses these and other risks and uncertainties under the heading “Risk Factors” in its annual and quarterly periodic reports filed with the SEC.  The Company may update that discussion in subsequent other periodic reports, but except as required by law, the Company undertakes no duty or obligation to update or revise these forward-looking statements, whether as a result of new information, future developments, or otherwise.

About Simon 
Simon is a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations and an S&P 100 company (Simon Property Group, NYSE: SPG). Our properties across North America, Europe and Asia provide community gathering places for millions of people every day and generate billions in annual sales.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/simon-property-group-announces-commencement-of-offering-of-common-stock-301175852.html

SOURCE Simon

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

  • Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group
  • Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%
  • Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved
  • Data demonstrates vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%
  • Companies plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the globe
  • The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021

NEW YORK and MAINZ, GERMANY, November 18, 2020Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 28 days after the first dose, 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.

There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group. To date, the Data Monitoring Committee for the study has not reported any serious safety concerns related to the vaccine. A review of unblinded reactogenicity data from the final analysis which consisted of a randomized subset of at least 8,000 participants 18 years and older in the Phase 2/3 study demonstrates that the vaccine was well tolerated, with most solicited adverse events resolving shortly after vaccination. The only Grade 3 (severe) solicited adverse events greater than or equal to 2% in frequency after the first or second dose were fatigue at 3.8% and headache at 2.0% following dose 2. Consistent with earlier shared results, older adults tended to report fewer and milder solicited adverse events following vaccination.

In addition, the companies announced that the safety milestone required by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved. Pfizer and BioNTech plan to submit a request within days to the FDA for an EUA based on the totality of safety and efficacy data collected to date, as well as manufacturing data relating to the quality and consistency of the vaccine. These data also will be submitted to other regulatory agencies around the world.

“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”

“We are grateful that the first global trial to reach the final efficacy analysis mark indicates that a high rate of protection against COVID-19 can be achieved very fast after the first 30 µg dose, underscoring the potential of BNT162 to provide early protection,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These achievements highlight the potential of mRNA as a new drug class. Our goal from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages. We believe we have successfully accomplished this with our vaccine candidate BNT162b2 in all age groups studied so far and look forward to sharing further details with the regulatory authorities. I want to thank all the devoted women and men who contributed to this historically unprecedented achievement. We will continue to work with our partners and governments around the world to prepare for global distribution in 2020 and beyond.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil and Argentina. The trial will continue to collect efficacy and safety data in participants for an additional two years.

Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021. Four of Pfizer’s facilities are part of the manufacturing and supply chain; St. Louis, MO; Andover, MA; and Kalamazoo, MI in the U.S.; and Puurs in Belgium. BioNTech’s German sites will also be leveraged for global supply.

Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world. The companies have developed specially designed, temperature-controlled thermal shippers utilizing dry ice to maintain temperature conditions of -70°C±10°C. They can be used be as temporary storage units for 15 days by refilling with dry ice. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment across their pre-set routes leveraging Pfizer’s broad distribution network.

Pfizer and BioNTech plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information contained in this release is as of November 18, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program, and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, anticipated timing of regulatory submissions and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data (including the Phase 3 data that is the subject of this release), including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial or in larger, more diverse populations upon commercialization; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when any biologics license and/or emergency use authorization applications may be filed in any jurisdictions for BNT162b2 or any other potential vaccine candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine candidate’s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to handling after delivery by Pfizer; the risk that we may not be able to successfully develop non-frozen formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit www.BioNTech.de.

BioNTech Forward-looking Statements

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any potential Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Pfizer Contacts:

Media Relations

Amy Rose
+1 (212) 733-7410
[email protected]

Investor Relations

Chuck Triano
+1 (212) 733-3901
[email protected]

BioNTech Contacts:

Media Relations

Jasmina Alatovic
+49 (0)6131 9084 1513 or +49 (0)151 1978 1385
[email protected]

Investor Relations

Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
[email protected]



Spire Increases Common Stock Dividend 18th Consecutive Year of Increases

PR Newswire

ST. LOUIS, Nov. 18, 2020 /PRNewswire/ — The board of directors of Spire Inc. (NYSE: SR) unanimously agreed to increase the quarterly common stock dividend to $0.65 per share from $0.6225 per share. This full year $0.11 increase brings the annualized rate to $2.60 per share.

“Spire’s growing dividend ensures that our investors benefit from another year of solid performance and its strong financial position. The Board of Directors is confident in our Company’s growth strategy and plans going forward. Growing our dividend is an integral part of how we deliver value to our shareholders and maintain Spire’s position as a compelling investment,” said Ed Glotzbach, chairman of the board of Spire.

The dividend is payable on January 5, 2021, to shareholders of record on December 11, 2020. Spire has continuously paid a cash dividend since 1946, with 2021 marking the Company’s 18th consecutive year of increasing its common stock dividend on an annualized basis.

The board of directors also declared the regular quarterly dividend of $0.36875 per depositary share on Spire’s 5.90 percent Series A Cumulative Redeemable Perpetual Preferred Stock payable February 15, 2021, to holders of record on January 25, 2021.

About Spire

At Spire Inc. (NYSE: SR) we believe energy exists to help make people’s lives better. It’s a simple idea, but one that’s at the heart of our company. Every day we serve 1.7 million homes and businesses making us the fifth largest publicly traded natural gas company in the country. We help families and business owners fuel their daily lives through our gas utilities serving Alabama, Mississippi and Missouri. Our natural gas-related businesses include Spire Marketing, Spire STL Pipeline and Spire Storage. We are committed to transforming our business through growing organically, investing in infrastructure, and advancing through innovation. Learn more at SpireEnergy.com.    

Investor Contact:
Scott W. Dudley Jr.
[email protected]  
314-342-0878

Media Contact:
Jessica B. Willingham
[email protected]  
314-342-3300

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/spire-increases-common-stock-dividend-18th-consecutive-year-of-increases-301175442.html

SOURCE Spire Inc.

CooTek (Cayman) Inc. to Hold Annual General Meeting on December 17, 2020

PR Newswire

SHANGHAI, Nov. 18, 2020 /PRNewswire/ — CooTek (Cayman) Inc. (“CooTek” or the “Company”) (NYSE: CTK), a fast-growing global mobile internet company, today announced that it will hold its annual general meeting of shareholders at 9F, Building T2, No.16, Lane 399, Xinlong Road, Shanghai, 201101, China on December 17, 2020 at 8:00 pm (HKT, local time). Due to the impacts of COVID-19 pandemic and the public health and travel restrictions, attendees unable to attend in person can join the meeting via virtual conference. To attend, please visit https://icaasia.zoom.us/webinar/register/WN_0LhLxq2ETGW59er0nulT3A,and the live webcast link will be emailed to members upon successful registration.

No proposal will be submitted for shareholder approval at the annual general meeting. Instead, the annual general meeting will serve as an open forum for shareholders and beneficial owners of the Company’s American depositary shares (“ADSs“) to discuss Company affairs with management.

The board of directors of the Company has fixed the close of business on November 19, 2020 as the record date (the “Record Date“) for determining the shareholders entitled to receive notice of the annual general meeting or any adjournment or postponement thereof.

Holders of record of the Company’s ordinary shares at the close of business on the Record Date are entitled to attend the annual general meeting and any adjournment or postponement thereof in person. Beneficial owners of the Company’s ADSs are welcome to attend the annual general meeting in person.

The Company has filed its annual report on Form 20-F (the “Annual Report“), which includes the Company’s audited financial statements for the fiscal year ended December 31, 2019, with the U.S. Securities and Exchange Commission (the “SEC“). The Company’s Annual Report can be accessed on the investor relations section of its website at https://ir.cootek.com, as well as on the SEC’s website at http://www.sec.gov/.

Holders of the Company’s ordinary shares or ADSs may obtain a hard copy of the Annual Report free of charge by emailing Mr. Robert Cui, CooTek (Cayman) Inc., at [email protected]or by writing to:

9F, T2 Building, NO.16, Lane 399, Xinlong Road
Shanghai 201101
People’s Republic of China
Attention: Robert Cui

About
CooTek (Cayman) Inc.

CooTek is a fast-growing mobile internet company with a global vision, offering mobile applications. Our mission is to empower everyone to enjoy relevant content seamlessly. The Company’s user-centric and data-driven approach has enabled it to release appealing products to capture mobile internet users’ ever-evolving content needs and helps it rapidly attract targeted users. CooTek has developed and brought to market content-rich mobile applications, focusing on three categories: online literature, scenario-based content apps and casual games.

Investor Relations Contacts

CooTek (Cayman) Inc.

Mr. Robert Cui
[email protected]  

Christensen

In China
Mr. Rene Vanguestaine
Phone: +86-10-5900-1548
E-mail: [email protected]   
In U.S.
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/cootek-cayman-inc-to-hold-annual-general-meeting-on-december-17-2020-301175834.html

SOURCE CooTek